TRAW 8-K: Earnings Release Furnished and Investor Presentation Posted

Rhea-AI Filing Summary

Traws Pharma, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025, and began using a new corporate investor presentation. The earnings release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2, and the presentation will be posted on the company website.

The disclosure in Item 7.01 is incorporated by reference into Item 2.02 but is explicitly furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings unless specifically referenced. The Current Report and its exhibits include customary forward‑looking statements and a risk disclaimer. The 8‑K body does not contain numeric financial results; investors must review Exhibits 99.1 and 99.2 for the full figures and context.

Positive

• Earnings press release for the quarter ended June 30, 2025 furnished as Exhibit 99.1
• New corporate investor presentation furnished as Exhibit 99.2 and to be posted on the company website
• Disclosure follows Regulation FD and clarifies the exhibits are furnished, not filed

Negative

• The 8-K body does not include numeric financial results; exhibits must be reviewed for details

Insights

Securities Analyst

TL;DR: Routine 8-K furnishing a Q2 earnings release and new investor deck; immediate investor impact depends on the exhibits' content.

As filed, the 8-K documents that the company furnished an earnings press release for the quarter ended June 30, 2025 (Exhibit 99.1) and a new investor presentation (Exhibit 99.2). Because the materials are furnished, not filed, the 8-K itself contains limited actionable financial detail. From an analyst perspective, the filing signals timely disclosure and refreshed investor materials, but any material implications for revenue, earnings, guidance, or cash position require review of the attached exhibits.

Investor Relations / Corporate Governance Specialist

TL;DR: Disclosure follows Regulation FD practices; presentation posting and forward‑looking disclaimer are standard and preserve disclosure controls.

The 8-K highlights compliance with Regulation FD by furnishing the earnings release and an updated corporate presentation and clarifies the legal treatment by stating the exhibits are furnished and not filed. The inclusion of a forward‑looking statements disclaimer is standard and reminds investors that actual results may differ due to risks identified in SEC filings. Governance and IR teams typically use this approach to ensure broad public dissemination while limiting incorporation risks.

false 0001130598 0001130598 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-36020		22-3627252
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

12 Penns Trail

Newtown, PA 18940

(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive
Offices)

Not Applicable 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $.01 per share	TRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition. 

The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) regarding the Earnings Release is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On August 14, 2025, Traws Pharma, Inc. (the “Company”) issued a press release (the “Earnings Release”) announcing its financial results for the quarter ended June 30, 2025, a copy of which is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Additionally, on August 14, 2025, the Company began using a new corporate presentation. A copy of that corporate presentation is furnished as Exhibit 99.2 hereto and incorporated herein by reference. The presentation will also be posted to the Company’s website.

The information set forth under Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

This Current Report, including Exhibits 99.1 and 99.2, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibits 99.1 and 99.2, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 14, 2025.
99.2		Investor Presentation, dated August 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2025	TRAWS PHARMA, INC.
	By:	/s/ Iain Dukes
		Iain Dukes
		Interim Chief Executive Officer

FAQ

What did Traws Pharma (TRAW) file in this Form 8-K?

The company furnished an earnings press release announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and furnished a new corporate investor presentation (Exhibit 99.2).

Does the 8-K itself include the quarterly financial numbers?

No. The 8-K states the earnings release is furnished as Exhibit 99.1, but the body of the 8-K does not contain numeric financial results.

Where can I find the full earnings details for TRAW Q2 2025?

Review Exhibit 99.1 attached to this 8-K and the company’s website where the investor presentation (Exhibit 99.2) will be posted for additional context.

Are the furnished exhibits considered 'filed' with the SEC?

No. The filing explicitly states Exhibits 99.1 and 99.2 are being furnished and shall not be deemed 'filed' under Section 18 of the Exchange Act and are not incorporated by reference except as expressly stated.

Does this 8-K include forward-looking statements?

Yes. The report and its exhibits contain forward‑looking statements and include a disclaimer that actual results may differ due to risks and uncertainties.